Inossia AB

Inossia AB is very happy and proud to be one of the selected projects awarded the sum of 7.3 million Euros from the European Innovation Council (EIC) Accelerator Program. The awarded sum is divided in 2.3 million euros in grant and 5.0 million euros in equity. The EIC Accelerator award supports, in particular start-ups and spinout companies, to develop and scale up game-changing innovations in the EU. The justification from the EIC is: ‘The jury considers this project to be a unique innovation with a high impact on a global and society level. The market size and societal impact is very significant, at a global scale.’ Less than 7% of all EIC applications were awarded. As a result of the EIC Accelerator project, we will be able to clinically validate two new bone cements with the Inossia Cement Softener: V-Flex for spinal fractures and Elastoment for degenerated discs. We will also be able to receive regulatory approvals in the EU and US, enter the markets and create a completely new product category for soft bone cement. There is a huge global challenge with the population growing older as osteoporosis affects 27.5 millon people in Europe and 14 millon people in the US (2020) and is the cause of almost 9 million bone fractures each year. Inossia is targeting two age-related conditions: - osteoporosis, affecting a third of the population over 50 and - degenerative discs disease, affecting more than half of the population over 50. Spinal fractures are one of the most common osteoporotic fractures. They can be treated by injecting bone cement into the fractured vertebra. It gives immediate pain relief but the bone cement used today is not adapted to the brittle bones in the osteoporotic spine. It is like injecting a stone into a pile of eggshells, - the next egg can break. Up to 40% of patients come back with new, painful and completely unnecessary fractures. Therefore, there is an urgent unmet need for a solution to treat spinal fractures effectively, allowing active ageing without pain in our increasingly elderly population. Degenerated discs could also easily be treated by injecting soft and elastic bone cement. It is a new market, with a clear need but no approved material yet. It gives Inossia the unique first mover potential. Our solution has the potential to reduce the number of new and unnecessary painful fractures by 75%. This will improve the quality of life for the patients and save costs for healthcare, says Malin Nilsson, CEO at Inossia. #eismea #grants #acceleratorprogram #inossia #softcement #spine #bonecement #osteoporosis #discoplasty #vertebroplasty https://lnkd.in/gZa7sprr

Strategy Day at Inossia AB! Today, the Inossia AB team — board members and all employees alike — came together for a full-day strategy session! It was an energizing day filled with discussions about our future perspectives, innovative ideas, and the exciting journey ahead. We took a deep dive into our goals, aligning on how we can continue to push boundaries and drive growth in our mission to revolutionize spinal health. Collaborating across all levels of the company provided valuable insights and strengthened our collective vision for the future. With everyone’s input, we explored fresh strategies, new opportunities, and challenges, positioning ourselves to embrace the next phase of innovation. Thanks to everyone for the dedication and the great ideas shared. Together, we’re shaping the future of Inossia! #StrategyDay #Teamwork #Innovation #FutureGrowth #InossiaAB #Spine

We're Expanding! We’re excited to announce that we’ve joined the Medicon Village in Lund! This move brings us closer to many innovative companies in the life sciences sector, providing a fantastic environment for collaboration and growth. Our Director of QA/RA, Anette Israelsson, is thrilled about the active networking opportunities at Medicon Village, including industry-focused groups in areas like regulatory affairs, quality assurance, and medical writing. Events like "Science for Breakfast" and lunch seminars foster a vibrant exchange of ideas. If you're in or around Lund, we’d love for you to stop by and say hello!

Day 2 of EUROSPINE, the Spine Society of Europe conference is in full swing here in Vienna! The energy is high, and the event is already buzzing with activity. Our Product Developer, Giannis Katsaros, is actively participating in insightful discussions on cutting-edge spinal care research. Stay tuned for more updates from this exciting event! If you are at the conference do not hesitate to visit us in Hall A at booth Q21 with G21 Srl! #Eurospine2024 #SpinalHealth #Innovation #Spine

First day at EUROSPINE, the Spine Society of Europe Vienna is almost done! Our CTO Peter Fröberg and Product Developer Giannis Katsaros have had a full day of engaging discussions and meetings about spinal care and #Vflex alongside G21 Srl. If you are at the conference do not hesitate to visit us in Hall A at booth Q21 and say hello! #Eurospine2024 #SpinalHealth #Innovation #Spine

Are you attending EUROSPINE, the Spine Society of Europe event in Vienna? We’d love to connect with you! Visit our team at booth Q21 in Hall A, where we'll be partnering with G21 Srl to showcase cutting-edge solutions in spine care. Hope to see you there! #Eurospine2024 #SpinalHealth #Vflex #Spine #Innovation

We are glad to have participated at LSI Europe, where our CEO presented Inossia AB and our latest developments in soft bone cements with #Vflex. If you did not have the opportunity at LSI Europe and would like to discuss our products, please reach out to our CEO or team! #LSIEurope #MedTech #BoneCement

In #Sweden, about 50% of women and 25% of men over the age of 50 are expected to suffer an osteoporosis-related fracture in their remaining lifetimes. Despite this, the Swedish health system does not prioritize early diagnosis and treatment, and only a fifth of patients receive pharmaceutical treatment after an osteoporotic fracture, according to experts. Read this insightful article newly published in Euractive. https://bit.ly/4dzEUla

In May Inossia had an external recertification audit of our Quality Management System for Medical Devices, ISO 13485:2016. RISE Research Institutes of Sweden AB carried out the audit. The ISO 13485:2016 certification was recertified without any problems. Today we got our certificate.

Ännu en viktig debattartikel av en klok kollega. Väl skrivet Anna Spångeus